AU2012352528B9 — Intranasal dexmedetomidine compositions and methods of use thereof
Assigned to Baudax Bio Inc · Expires 2017-11-02 · 9y expired
What this patent protects
The present invention provides intranasal formulations comprising dexmedetomidine, or a pharmaceutically acceptable salt thereof, that are analgesic but without significant sedation, methods of treating or preventing pain comprising administering the intranasal formulations to a …
USPTO Abstract
The present invention provides intranasal formulations comprising dexmedetomidine, or a pharmaceutically acceptable salt thereof, that are analgesic but without significant sedation, methods of treating or preventing pain comprising administering the intranasal formulations to a mammal and metered dose devices for administering the intranasal formulation as a spray, wherein the droplets of the spray have a Dv90 of less than 150 urn.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.